Additionally, immunotherapy-activated CD8+ T cells can down-regulate the expression of SLC3A2 and SLC7A11 by releasing interferon-γ (IFNγ), and increase the specific lipid peroxidation and ferroptosis of tumor cells, thereby enhancing the anti-tumor efficacy of immunotherapy, indicating that ferroptosis and immunotherapy have a positive feedback and kill cancer cells together (15). Here, SLC3A2 is linked to neoplasm.